Computer programs used in the field of hospital pharmacy for the management of dangerous drugs: systematic review of literature.
Hospital Pharmacy
antineoplastic agents
cytostatic agents
hazardous substances
medical informatics applications
occupational health
patient safety
software
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
06
2023
accepted:
14
08
2023
medline:
18
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
This review wants to highlight the importance of computer programs used to control the steps in the management of dangerous drugs. It must be taken into account that there are phases in the process of handling dangerous medicines in pharmacy services that pose a risk to the healthcare personnel who handle them. Objective: To review the scientific literature to determine what computer programs have been used in the field of hospital pharmacy for the management of dangerous drugs (HDs). The following electronic databases were searched from inception to July 30, 2021: MEDLINE (via PubMed), Embase, Cochrane Library, Scopus, Web of Science, Latin American and Caribbean Literature in Health Sciences (LILACS) and Medicine in Spanish (MEDES). The following terms were used in the search strategy: "Antineoplastic Agents," "Cytostatic Agents," "Hazardous Substances," "Medical Informatics Applications," "Mobile Applications," "Software," "Software Design," and "Pharmacy Service, Hospital." A total of 104 studies were retrieved form the databases, and 18 additional studies were obtained by manually searching the reference lists of the included studies and by consulting experts. Once the inclusion and exclusion criteria were applied, 26 studies were ultimately included in this review. Most of the applications described in the included studies were used for the management of antineoplastic drugs. The most commonly controlled stage was electronic prescription; 18 studies and 7 interventions carried out in the preparation stage focused on evaluating the accuracy of chemotherapy preparations. Antineoplastic electronic prescription software was the most widely implemented software at the hospital level. No software was found to control the entire HD process. Only one of the selected studies measured safety events in workers who handle HDs. Moreover, health personnel were found to be satisfied with the implementation of this type of technology for daily work with these medications. All studies reviewed herein considered patient safety as their final objective. However, none of the studies evaluated the risk of HD exposure among workers.
Sections du résumé
Background
This review wants to highlight the importance of computer programs used to control the steps in the management of dangerous drugs. It must be taken into account that there are phases in the process of handling dangerous medicines in pharmacy services that pose a risk to the healthcare personnel who handle them. Objective: To review the scientific literature to determine what computer programs have been used in the field of hospital pharmacy for the management of dangerous drugs (HDs).
Methods
The following electronic databases were searched from inception to July 30, 2021: MEDLINE (via PubMed), Embase, Cochrane Library, Scopus, Web of Science, Latin American and Caribbean Literature in Health Sciences (LILACS) and Medicine in Spanish (MEDES). The following terms were used in the search strategy: "Antineoplastic Agents," "Cytostatic Agents," "Hazardous Substances," "Medical Informatics Applications," "Mobile Applications," "Software," "Software Design," and "Pharmacy Service, Hospital."
Results
A total of 104 studies were retrieved form the databases, and 18 additional studies were obtained by manually searching the reference lists of the included studies and by consulting experts. Once the inclusion and exclusion criteria were applied, 26 studies were ultimately included in this review. Most of the applications described in the included studies were used for the management of antineoplastic drugs. The most commonly controlled stage was electronic prescription; 18 studies and 7 interventions carried out in the preparation stage focused on evaluating the accuracy of chemotherapy preparations.
Conclusion
Antineoplastic electronic prescription software was the most widely implemented software at the hospital level. No software was found to control the entire HD process. Only one of the selected studies measured safety events in workers who handle HDs. Moreover, health personnel were found to be satisfied with the implementation of this type of technology for daily work with these medications. All studies reviewed herein considered patient safety as their final objective. However, none of the studies evaluated the risk of HD exposure among workers.
Identifiants
pubmed: 37711235
doi: 10.3389/fpubh.2023.1233264
pmc: PMC10498460
doi:
Types de publication
Journal Article
Review
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233264Informations de copyright
Copyright © 2023 Climent-Ballester, García-Salom and Sanz-Valero.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Med Inform. 2010 Oct;79(10):699-706
pubmed: 20829102
J Oncol Pract. 2014 Mar;10(2):e113-9
pubmed: 24371301
J Am Med Inform Assoc. 2013 May 1;20(3):470-6
pubmed: 23425440
Ther Innov Regul Sci. 2020 Jan;54(1):85-92
pubmed: 32008248
J Clin Pharm Ther. 2015 Feb;40(1):32-40
pubmed: 25303720
Clin Transl Oncol. 2006 Nov;8(11):821-5
pubmed: 17134971
Ann Pharm Fr. 2014 Jan;72(1):33-40
pubmed: 24438667
Arch Prev Riesgos Labor. 2021 Jul 15;24(3):263-296
pubmed: 34965332
BMJ Open. 2019 Dec 11;9(12):e032528
pubmed: 31831544
J Oncol Pract. 2011 Jul;7(4):218-22
pubmed: 22043183
Am J Health Syst Pharm. 2001 Oct 1;58(19):1835-41
pubmed: 11596700
J Oncol Pharm Pract. 2017 Mar;23(2):83-92
pubmed: 26637408
Pharm World Sci. 2001 Jun;23(3):102-6
pubmed: 11468873
J Oncol Pharm Pract. 2021 Jul;27(5):1205-1213
pubmed: 33736555
PLoS One. 2021 Jul 1;16(7):e0253909
pubmed: 34197532
Stud Health Technol Inform. 2009;143:309-14
pubmed: 19380953
Br J Nutr. 2012 Jun;107 Suppl 2:S3-7
pubmed: 22591902
PLoS One. 2018 May 11;13(5):e0197172
pubmed: 29750798
J Oncol Pharm Pract. 2008 Dec;14(4):181-7
pubmed: 18753187
J Oncol Pract. 2012 Nov;8(6):344-9, 1 p following 349
pubmed: 23598843
Farm Hosp. 2015 May 01;39(3):137-46
pubmed: 26005888
JMIR Mhealth Uhealth. 2021 Sep 9;9(9):e27021
pubmed: 34499044
Int J Qual Health Care. 2013 Dec;25(6):656-63
pubmed: 24132956
Arch Prev Riesgos Labor. 2014 Jul-Sep;17(3):142-53
pubmed: 25022532
JAMA. 1995 Jul 5;274(1):35-43
pubmed: 7791256
J Eval Clin Pract. 2016 Apr;22(2):253-60
pubmed: 26552362
Med Clin (Barc). 2004 Jun 5;123(1):21-5
pubmed: 15207224
Med J Islam Repub Iran. 2021 Feb 22;35:27
pubmed: 34169039
Gac Sanit. 2008 Mar-Apr;22(2):144-50
pubmed: 18420014
Arch Prev Riesgos Labor. 2021 Jan 21;24(1):47-61
pubmed: 33691039
Qual Saf Health Care. 2006 Dec;15(6):418-21
pubmed: 17142590
Farm Hosp. 2017 Jan 01;41(n01):89-104
pubmed: 28045654
BMJ. 2001 Aug 11;323(7308):334-6
pubmed: 11498496
Pharm World Sci. 1996 Oct;18(5):178-81
pubmed: 8933578
J Pharm Health Care Sci. 2017 Apr 24;3:12
pubmed: 28451441
Ann Oncol. 2015 May;26(5):981-986
pubmed: 25632069
Noise Health. 2016 Sep-Oct;18(84):229-239
pubmed: 27762251
Int J Qual Health Care. 2011 Feb;23(1):36-43
pubmed: 21084323
Health Serv Res. 2008 Feb;43(1 Pt 1):32-53
pubmed: 18211517
J Clin Pharm Ther. 2017 Aug;42(4):446-453
pubmed: 28429389
J Formos Med Assoc. 2013 Apr;112(4):193-200
pubmed: 23537865
Rev Chilena Infectol. 2014 Dec;31(6):705-18
pubmed: 25679928
BMC Health Serv Res. 2013 Dec 17;13:522
pubmed: 24344973
BMJ. 2004 Jan 3;328(7430):39-41
pubmed: 14703546
J Oncol Pract. 2014 Jan;10(1):e5-9
pubmed: 24003174
Qual Saf Health Care. 2007 Oct;16(5):369-77
pubmed: 17913779
J Natl Compr Canc Netw. 2010 Sep;8 Suppl 7:S7-S27
pubmed: 20947724
Br J Haematol. 2004 Apr;125(1):50-7
pubmed: 15015968
Lancet. 1979 Jun 9;1(8128):1250-1
pubmed: 87722
Farm Hosp. 2020 Mar 01;44(2):51-61
pubmed: 32452316
J Oncol Pract. 2011 Jul;7(4):233-7
pubmed: 22043187
Arch Pediatr Adolesc Med. 2006 May;160(5):495-8
pubmed: 16651491